Smooth muscle-specific expression of calcium-independent phospholipase A2β (iPLA2β) participates in the initiation and early progression of vascular inflammation and neointima formation.
Whether group VIA phospholipase A(2) (iPLA(2)β) is involved in vascular inflammation and neointima formation is largely unknown. Here, we report that iPLA(2)β expression increases in the vascular tunica media upon carotid artery ligation and that neointima formation is suppressed by genetic deletion of iPLA(2)β or by inhibiting its activity or expression via perivascular delivery of bromoenol lactone or of antisense oligonucleotides, respectively. To investigate whether smooth muscle-specific iPLA(2)β is involved in neointima formation, we generated transgenic mice in which iPLA(2)β is expressed specifically in smooth muscle cells and demonstrate that smooth muscle-specific expression of iPLA(2)β exacerbates ligation-induced neointima formation and enhanced both production of proinflammatory cytokines and vascular infiltration by macrophages. With cultured vascular smooth muscle cell, angiotensin II, arachidonic acid, and TNF-α markedly induce increased expression of IL-6 and TNF-α mRNAs, all of which were suppressed by inhibiting iPLA(2)β activity or expression with bromoenol lactone, antisense oligonucleotides, and genetic deletion, respectively. Similar suppression also results from genetic deletion of 12/15-lipoxygenase or inhibiting its activity with nordihydroguaiaretic acid or luteolin. Expression of iPLA(2)β protein in cultured vascular smooth muscle cells was found to depend on the phenotypic state and to rise upon incubation with TNF-α. Our studies thus illustrate that smooth muscle cell-specific iPLA(2)β participates in the initiation and early progression of vascular inflammation and neointima formation and suggest that iPLA(2)β may represent a novel therapeutic target for preventing cardiovascular diseases.
Department of Internal Medicine, University of Kentucky School of Medicine, Lexington, Kentucky 40536, USA.
Shu
S
Liu
Zhongwen
Z
Xie
Qingwei
Q
Zhao
Huan
H
Pang
John
J
Turk
Lindsay
L
Calderon
Wen
W
Su
Guogang
G
Zhao
Haifei
H
Xu
Ming C
MC
Gong
Zhenheng
Z
Guo
D000804:Angiotensin II; D000818:Animals; D015153:Blotting, Western; D002118:Calcium / Q000378:metabolism*; D002339:Carotid Arteries / Q000276:immunology / Q000378:metabolism; D002478:Cells, Cultured; D007150:Immunohistochemistry; D007249:Inflammation / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009131:Muscle, Smooth, Vascular / Q000276:immunology* / Q000378:metabolism*; D058426:Neointima / Q000276:immunology* / Q000378:metabolism*; D016376:Oligonucleotides, Antisense; D054512:Phospholipases A2, Calcium-Independent / Q000235:genetics / Q000378:metabolism*; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic / Q000235:genetics; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley
D016376:Oligonucleotides, Antisense; D000804:Angiotensin II; D054512:Phospholipases A2, Calcium-Independent; D002118:Calcium